Baillie Gifford & Co
NKTR icon

Baillie Gifford & Co’s Nektar Therapeutics NKTR Stock Holding History

Baillie Gifford & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-92
Closed -$967 – 391
2023
Q1 		$967 Hold
92
– – ﹤0.01% 444
2022
Q4 		$3.11K Hold
92
– – ﹤0.01% 464
2022
Q3 		$4K Hold
92
– – ﹤0.01% 455
2022
Q2 		$5K Hold
92
– – ﹤0.01% 452
2022
Q1 		$7K Hold
92
– – ﹤0.01% 455
2021
Q4 		$19K Hold
92
– – ﹤0.01% 385
2021
Q3 		$25K Sell
92
-11
-11% -$2.65K ﹤0.01% 339
2021
Q2 		$26K Hold
103
– – ﹤0.01% 331
2021
Q1 		$31K Buy
103
+2
+2% +$622 ﹤0.01% 299
2020
Q4 		$26K Buy
+101
New +$26.1K ﹤0.01% 303

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Baillie Gifford & Co's NKTR Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 92 shares — an estimated $967 sold.

Baillie Gifford & Co first reported a position in NKTR in Q4 2020 and held it in 10 quarters. The position peaked at $31K in Q1 2021. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 92 Nektar Therapeutics shares in Q2 2023, an estimated $967.
  • Baillie Gifford & Co first reported a position in Nektar Therapeutics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Nektar Therapeutics position peaked at $31K in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.